Ultragenyx Pharmaceutical Inc.
RARE
$26.96
$0.160.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 214.00M | 136.00M | 207.28M | 159.93M | 167.00M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 214.00M | 136.00M | 207.28M | 159.93M | 167.00M |
| Cost of Revenue | 201.00M | 189.00M | 232.63M | 244.20M | 188.00M |
| Gross Profit | 13.00M | -53.00M | -25.35M | -84.27M | -21.00M |
| SG&A Expenses | 88.00M | 86.00M | 87.94M | 86.62M | 87.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 289.00M | 275.00M | 320.56M | 330.82M | 275.00M |
| Operating Income | -75.00M | -139.00M | -113.28M | -170.89M | -108.00M |
| Income Before Tax | -91.00M | -184.00M | -127.69M | -179.54M | -114.00M |
| Income Tax Expenses | 1.00M | 1.00M | 870.00K | 873.00K | 1.00M |
| Earnings from Continuing Operations | -92.00M | -185.00M | -128.56M | -180.41M | -115.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -92.00M | -185.00M | -128.56M | -180.41M | -115.00M |
| EBIT | -75.00M | -139.00M | -113.28M | -170.89M | -108.00M |
| EBITDA | -67.00M | -131.00M | -104.50M | -162.28M | -99.00M |
| EPS Basic | -0.90 | -1.84 | -1.29 | -1.81 | -1.17 |
| Normalized Basic EPS | -0.56 | -0.96 | -0.80 | -1.13 | -0.72 |
| EPS Diluted | -0.90 | -1.84 | -1.29 | -1.81 | -1.17 |
| Normalized Diluted EPS | -0.56 | -0.96 | -0.80 | -1.13 | -0.72 |
| Average Basic Shares Outstanding | 101.90M | 100.60M | 99.90M | 99.77M | 98.50M |
| Average Diluted Shares Outstanding | 101.90M | 100.60M | 99.90M | 99.77M | 98.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |